Literature DB >> 19804919

Regional trends in multidrug-resistant infections in German intensive care units: a real-time model for epidemiological monitoring and analysis.

A Kohlenberg1, F Schwab, E Meyer, M Behnke, C Geffers, P Gastmeier.   

Abstract

A new surveillance module for multidrug-resistant (MDR) bacteria was added to the intensive care component of the German Nosocomial Infection Surveillance System. Participating intensive care units (ICUs) report data on all patients colonised or infected with meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EC/KP). To determine the regional distribution of MRSA, VRE and ESBL-EC/KP in Germany, incidence densities (IDs) of these bacteria per 1000 patient-days were calculated for each ICU and pooled for ICUs of five German regions for the years 2005 and 2006. A total of 176 ICUs including 284 142 patients and 1 021 579 patient-days reported data concerning 5490 cases of MDR bacteria. The pooled IDs were 4.54, 0.54 and 0.29 cases per 1000 patient-days for MRSA, ESBL-EC/KP and VRE cases and 1.56, 0.32 and 0.13 per 1000 patient-days for MRSA, ESBL-EC/KP and VRE infections, respectively. While there were no significant differences in the incidence densities of MRSA infections between regions, the IDs of VRE and ESBL-EC/KP infections showed significant regional variation. The regions also differed in the proportion of ICUs per region that reported at least one infection with MRSA, ESBL-EC/KP or VRE in 2005-2006 and these differences ranged from 82% to 91% for MRSA, from 34% to 76% for ESBL-EC/KP and from 8% to 42% for VRE. This new surveillance module enables ICUs to monitor the occurrence of MDR bacteria by comparing local incidence densities with a national reference and shows significant regional variation of MDR bacteria in Germany.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804919     DOI: 10.1016/j.jhin.2009.07.017

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  7 in total

Review 1.  The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Germany.

Authors:  Robin Köck; Alexander Mellmann; Frieder Schaumburg; Alexander W Friedrich; Frank Kipp; Karsten Becker
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

2.  Intracellular localization of polymyxins in human alveolar epithelial cells.

Authors:  Maizbha U Ahmed; Tony Velkov; Qi Tony Zhou; Alex J Fulcher; Judy Callaghan; Fanfan Zhou; Kim Chan; Mohammad A K Azad; Jian Li
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

Review 3.  Control of the spread of vancomycin-resistant enterococci in hospitals: epidemiology and clinical relevance.

Authors:  Nico T Mutters; Volker Mersch-Sundermann; Reinier Mutters; Christian Brandt; Wulf Schneider-Brachert; Uwe Frank
Journal:  Dtsch Arztebl Int       Date:  2013-10-25       Impact factor: 5.594

4.  Screening and control of methicillin-resistant Staphylococcus aureus in 186 intensive care units: different situations and individual solutions.

Authors:  Anke Kohlenberg; Frank Schwab; Michael Behnke; Christine Geffers; Petra Gastmeier
Journal:  Crit Care       Date:  2011-11-25       Impact factor: 9.097

5.  Evaluation of vancomycin therapy in the adult ICUs of a teaching hospital in southern Iran.

Authors:  Afsaneh Vazin; Motahare Mahi Birjand; Masoud Darake
Journal:  Drug Healthc Patient Saf       Date:  2018-04-05

6.  Individual units rather than entire hospital as the basis for improvement: the example of two Methicillin resistant Staphylococcus aureus cohort studies.

Authors:  Petra Gastmeier; Frank Schwab; Iris Chaberny; Christine Geffers
Journal:  Antimicrob Resist Infect Control       Date:  2012-02-13       Impact factor: 4.887

7.  Incidence of and risk factors for infection or colonization of vancomycin-resistant enterococci in patients in the intensive care unit.

Authors:  Sung-Ching Pan; Jann-Tay Wang; Yee-Chun Chen; Yin-Yin Chang; Mei-Ling Chen; Shan-Chwen Chang
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.